Scarica l'app Stockscreener
20.78
4.55%
-0.99
Dopo l'orario di chiusura:
21.13
0.35
+1.68%
Uniqure N V Borsa (QURE) Ultime notizie
Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat
Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat
Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat
Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ
uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
How uniQure N.V. (UQ1) stock benefits from digital adoptionTrade Ideas & Scalable Portfolio Growth Methods - Newser
How strong is uniQure N.V. stock revenue growthJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
uniQure (QURE) Is Down 17.3% After FDA Questions AMT-130 Data Sufficiency For BLAHas The Bull Case Changed? - simplywall.st
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Enc - GuruFocus
uniQure (QURE) Stock: Navigates Regulatory Hurdles for AMT-130 as FDA Requests Further Engagement - parameter.io
uniQure (QURE) Analyst Ratings: Chardan Capital Maintains Buy Ra - GuruFocus
Why uniQure Stock Is Trading Lower After FDA Meeting Update - Benzinga
uniQure N.V. (QURE): A Bear Case Theory - Finviz
uniQure (QURE) Shares Plunge 20% on FDA Feedback for AMT-130 - GuruFocus
uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA - TipRanks
uniQure stock falls after FDA signals data unlikely to support AMT-130 approval - Investing.com Australia
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
uniQure stock falls after FDA's notes on pre application of AMT-130 - Seeking Alpha
uniQure (QURE) Reassesses Strategy After FDA Feedback on AMT-130 Application - GuruFocus
UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission - marketscreener.com
Why Is UniQure Stock Falling In Pre-market? - Nasdaq
uniQure Faces Setback in Gene Therapy Approval - TipRanks
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - The Manila Times
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView
Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease - marketscreener.com
uniQure (NASDAQ: QURE) receives FDA minutes on AMT-130 BLA path for Huntington’s disease - Stock Titan
uniQure N.V. $QURE Stake Reduced by Schroder Investment Management Group - MarketBeat
uniQure N.V. $QURE Shares Acquired by JPMorgan Chase & Co. - MarketBeat
(QURE) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
uniQure N.V. (UQ1) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Smart Money Is Betting Big In QURE Options - Benzinga
Can uniQure N.V. stock sustain institutional interestDip Buying & Stock Portfolio Risk Management - Newser
Will uniQure N.V. (UQ1) stock draw ESG focused fundsQuarterly Growth Report & Long-Term Capital Growth Ideas - Newser
QURE Investigation: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
How uniQure N.V. stock performs in weak economy2025 Stock Rankings & AI Forecasted Stock Moves - Newser
Will uniQure N.V. (UQ1) stock sustain uptrend momentumJuly 2025 Momentum & Community Consensus Picks - Newser
Can uniQure N.V. (UQ1) stock sustain revenue momentumWeekly Profit Report & Detailed Earnings Play Strategies - Newser
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
ETF Watch: How strong is uniQure NV stock revenue growthJuly 2025 Rallies & Stock Portfolio Risk Management - BỘ NỘI VỤ
Wall Street Zen Upgrades uniQure (NASDAQ:QURE) to Hold - MarketBeat
uniQure N.V. (QURE) Options Chain - Yahoo! Finance Canada
How uniQure N.V. stock benefits from tech adoptionEarnings Growth Report & Expert Curated Trade Setups - BỘ NỘI VỤ
uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - MSN
William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty - MSN
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):